Abstract
The pan BCL-2 inhibitor sabutoclax sensitizes dormant CML stem cells to dasatinib treatment.
- ©2013 American Association for Cancer Research.
The pan BCL-2 inhibitor sabutoclax sensitizes dormant CML stem cells to dasatinib treatment.
Published OnlineFirst January 24, 2013
doi: 10.1158/2159-8290.CD-RW2013-020